Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Against the backdrop of a growing chikungunya epidemic in La Réunion, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ® vaccine in vulnerable individuals (seniors, comorbid patients), defined by the French Health Autority (HAS) as at risk of severe or complicated forms and/or chronic disabling forms (chronic arthritis, chronic fatigue phenotypes). This study will also provide input for the preparation of a cluster randomized trial on a population scale.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
1,800 participants in 2 patient groups
Loading...
Central trial contact
Patrick GERARDIN, MD; Laetitia Berly
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal